Humans ; Class I Phosphatidylinositol 3-Kinases/genetics* ; Breast Neoplasms/diagnosis* ; Mutation ; Female ; China ; DNA Mutational Analysis/methods* ; Genetic Testing/standards*

Humans ; Colorectal Neoplasms/pathology* ; Pathology, Molecular/methods* ; Biomarkers, Tumor/genetics* ; Genetic Testing ; China

Humans ; Glioma/metabolism* ; Consensus ; China ; Brain Neoplasms/pathology* ; Pathology, Molecular

Humans ; Ovarian Neoplasms/metabolism* ; Female ; Biomarkers, Tumor/metabolism* ; Mutation

Humans ; Consensus ; High-Throughput Nucleotide Sequencing/standards* ; Neoplasms/diagnosis* ; Quality Control ; Sequence Analysis, DNA/methods* ; Sequence Analysis, RNA/methods*

Humans ; Thyroid Neoplasms/metabolism* ; Consensus ; Thyroidectomy ; China ; Immunohistochemistry ; Postoperative Period

Humans ; Biomarkers, Tumor/metabolism* ; Claudins/analysis* ; Consensus ; Immunohistochemistry/methods* ; Stomach Neoplasms/diagnosis*

Humans ; Ovarian Neoplasms/drug therapy* ; Folate Receptor 1/metabolism* ; Female ; Immunohistochemistry/standards* ; Consensus ; Biomarkers, Tumor/metabolism* ; Fallopian Tube Neoplasms/pathology*

Large B-cell lymphoma(LBCL),formerly known as diffuse large B-cell lymphoma(DLBCL),is the most common type of lymphoma,characterized by high invasiveness and strong heterogeneity.The World Health Organ-ization(WHO)lymphoma classification has been continually updated to better differentiate the biological behaviors of various subtypes of DLBCL.These updated classifications are increasingly important for prognosis stratification and treatment decisions for oncologists.The increasingly refined classification of DLBCL will inevitably require pathologists to make more precise diagnoses.Furthermore,the advances and growing diversity in lymphoma treatment also create a demand for precision diagnosis in LBCL,including therapy-target evaluation.Based on our own experience,we have systematically reviewed and summarized the current knowledge and progress in precision diagnosis of LBCL.This re-view aims to emphasize the importance of precision diagnosis in LBCL,help readers understand the relevant concepts more comprehensively and accurately,and promote the adoption of more reasonable diagnostic procedures.

EBER in-situ hybridization detection technology is a method used to detect the expression and localiza-tion of RNA molecules in tissuess and cells.Standardized detection is fundamental to ensuring the accuracy of the re-sults.To address key issues in the clinical application of EBER in-situ hybridization detection technology,Pathological Technical Expert Group of Medical Technician Committee of Chinese Medical Doctor Association,Standardization De-partment of China Association of Pathology Equipment,Pathological Technology Group of Pathological Committee of China Anti-cancer Association,and Pathological Technology Group of Pathology Committee of Chinese Research Hospi-tal Association organized experts from related fields to conduct in-depth discussions and reached this consensus.This consensus covers aspects such as the principle of EBER in-situ hybridization detection technology,sample processing standards,standards operating procedures,and quality control protocols.It aims to provide guidance for clinical labora-tories to carry out EBER in-situ hybridization detection,as well as improving the accuracy and reliability of detection results.